Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_2

40%

Ph phase_1

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

3(60.0%)

Phase 2Efficacy & side effects

2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(2)

Detailed Status

Completed3

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (60.0%)

Phase 22 (40.0%)

Trials by Status

completed360%

terminated240%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_1

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

NCT00772486

terminatedphase_2

Study of Repeat Intranodal Injections of Ad-ISF35

NCT00942409

terminatedphase_2

Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT00849524

completedphase_1

A Phase I Extension Trial of Repeated Infusions of ISF35

NCT00783588

completedphase_1

A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

NCT00779883

Clinical Trials (5)

Showing 5 of 5 trials

NCT00772486Phase 1

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

Completed

NCT00942409Phase 2

Study of Repeat Intranodal Injections of Ad-ISF35

Terminated

NCT00849524Phase 2

Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Terminated

NCT00783588Phase 1

A Phase I Extension Trial of Repeated Infusions of ISF35

Completed

NCT00779883Phase 1

A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

Completed

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5